Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 1
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of MRG-110 Following Local Intradermal Injection After Skin Excisional Wound Creation in Normal Healthy Volunteers
Healthy Volunteer
Enrolment: 42 · Results not recorded
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseWounddb/db mice; normal pigs
Model: Excisional cutaneous wounds in db/db mice (chronic/diabetic) and in normal pigs (acute)
MRG-110 increased granulation tissue, angiogenesis and perfusion, and accelerated wound closure in both acute and chronic wounds, with effects greater than rhVEGF-165 and rhPDGF-BB and at least additive with rhPDGF-BB. No safety concerns were noted.
Extraction: extract · Supplied extraction confidence: 0.62. Machine-extracted fields require source verification.